根据Exact Sciences的建模数据预测，在过去10年中，已有超过1600万人通过Cologuard测试完成了筛查。这也推动了美国50-75岁群体的结肠癌筛查率，从2015年的63%上升到2021年的72%。

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

周一，Canaccord Genuity重申了Exact Sciences Corporation (NASDAQ:EXAS)的买入评级，并维持75美元的目标价。这一背书是在该公司在2024年欧洲医学肿瘤学会（ESMO）大会上宣布其基于血液的结直肠癌（CRC）筛查测试的新性能数据之后做出的。 这项旨在提高新型生物标志物特异性的测试显示，对CRC的检测敏感性为88%，对进展性腺瘤（AA）的敏感性为3 ...

周一，Citi重申了对Exact Sciences (NASDAQ:EXAS)的买入评级和80.00美元的股票目标价，此举是在该公司发布了其基于血液的结直肠癌 (CRC)测试的初步积极数据之后。该测试显示整体CRC敏感性为88.3%，特异性为90.1%，晚期腺瘤 (AA)敏感性为31.2%。

The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Recommended Reading Guardant wins ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...